Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

Revenue rose 10% to $3.79 billion, surpassing the average $3.74 billion target from analysts polled by FactSet. Sales of the EYLEA HD more than doubled to $305 million. The medication was approved for ...